Ewan Walters

Dr Ewan Walters Qualified in Biochemistry and Medicine from the University of Bristol in 1979 and worked in several clinical roles within Bristol and Cardiff Hospitals over the next 4 years. He joined the Pharmaceutical industry in 1983 as part of the Medical team that was responsible for registering aspartame across Europe and managing the re-licensing of all products for Searle-Monsanto during the period of 1983-5 as part of the Committee for the review of Medicines (CRM) process that was initiated by the UK regulatory Authorities. After several clinical roles within the company as part of both R and D and Medical Affairs Teams he was appointed Medical Director of Lorex Pharmaceuticals which was a joint venture between Searle Monsanto and Synthelabo of France.

During this period he worked in many areas of medicine including cardiology, gastroenterology, psychiatry, urinary medicine, anti-infectives, pain and women’s health. In 1996 he was appointed to the role of Vice-President Europe Medical Affairs for ICN Pharmaceuticals where the main focus was on the development of ribavirin for use in combination with interferon for the treatment of hepatitis C and other viral conditions. After 2 years as a consultant and Interim manager he was appointed to Medical Director of Teva UK Limited in 2007 to present time. During this role development of inhalers and respiratory treatments for asthma and COPD has been a major focus with Medical Affairs activities in most areas of medicine owing to the extensive portfolio of medicines currently marketed by his company.